Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of market approval for CMAB807, a biosimilar version of Johnson & Johnson (J&J, NYSE: JNJ)’s Remicade (infliximab), in Pakistan. This follows similar approvals in Peru and Indonesia last year. The approval encompasses all six indications, which include adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, adult and childhood Crohn’s disease, fistula Crohn’s disease, and psoriasis.
Global Expansion of CMAB807
CMAB807’s market approval in Pakistan further expands the global reach of this biosimilar product. The drug is already approved in several countries, demonstrating its potential to address the needs of patients with various autoimmune conditions and inflammatory diseases.
CMAB008: The First Infliximab Copycat Approved in China
CMAB008, the first infliximab copycat approved in China, was licensed to Kexing Biopharm (SHA: 688136) in June 2021 for exclusive promotion globally, excluding mainland China, Japan, Europe, and North America. This deal was expanded in March 2022 to include mainland China, highlighting the growing acceptance and demand for biosimilar drugs in the global market.-Fineline Info & Tech
